RGD-Modified Nano-Liposomes Encapsulated Eptifibatide with Proper Hemocompatibility and Cytotoxicity Effect.
Cytotoxicity
Eptifibatide
Liposomes
Materials Testing
Journal
Iranian journal of biotechnology
ISSN: 1728-3043
Titre abrégé: Iran J Biotechnol
Pays: Iran
ID NLM: 101276796
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
29
8
2019
Statut:
epublish
Résumé
Eptifibatide (Integrilin®) is a hepta-peptide drug which specifically prevents the aggregation of activated platelets. The peptide drugs are encapsulated into nanolipisomes in order to decreasing their side effects and improving their half-life and bioavailability. In this study, the RGD-MNL encapsulated eptifibatide was prepared using lipid film hydration and freeze/thawing method. The morphology and size distribution (about 90 nm) of RGD-MNL were characterized using transmission electron microscopy (TEM). The The results revealed that RGD-MNL had no significant cytotoxic effect on HeLa and HUVEC cell lines, and also no ROS generation increase in the cells. In addition, the adverse effect of RGD-MNL on LDH release and membrane integrity of RBC was not observed. In conclusion, the recommended RGD-MNL formulations have not any significant cytotoxicity on normal cells or RBC and have potential for protecting and enhancing the activity of antiplatelet drugs.
Sections du résumé
BACKGROUND
BACKGROUND
Eptifibatide (Integrilin®) is a hepta-peptide drug which specifically prevents the aggregation of activated platelets. The peptide drugs are encapsulated into nanolipisomes in order to decreasing their side effects and improving their half-life and bioavailability.
OBJECTIVES
OBJECTIVE
In this study, the
MATERIAL AND METHODS
METHODS
RGD-MNL encapsulated eptifibatide was prepared using lipid film hydration and freeze/thawing method. The morphology and size distribution (about 90 nm) of RGD-MNL were characterized using transmission electron microscopy (TEM). The
RESULTS
RESULTS
The results revealed that RGD-MNL had no significant cytotoxic effect on HeLa and HUVEC cell lines, and also no ROS generation increase in the cells. In addition, the adverse effect of RGD-MNL on LDH release and membrane integrity of RBC was not observed.
CONCLUSIONS
CONCLUSIONS
In conclusion, the recommended RGD-MNL formulations have not any significant cytotoxicity on normal cells or RBC and have potential for protecting and enhancing the activity of antiplatelet drugs.
Identifiants
pubmed: 31457055
doi: 10.21859/ijb.2008
pmc: PMC6697844
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2008Références
Pharm Res. 2000 May;17(5):521-5
pubmed: 10888302
Methods Mol Biol. 2000;99:35-47
pubmed: 10909075
Free Radic Biol Med. 2000 Aug;29(3-4):222-30
pubmed: 11035250
Expert Opin Investig Drugs. 1999 Nov;8(11):1893-1905
pubmed: 11139832
J Control Release. 2002 Jan 17;78(1-3):235-47
pubmed: 11772464
J Vasc Surg. 2006 Apr;43(4):816-23
pubmed: 16616242
Int J Pharm. 2007 Feb 7;330(1-2):14-22
pubmed: 16997516
Cancer Chemother Pharmacol. 2008 Jul;62(2):285-92
pubmed: 17922275
Biomaterials. 2008 Apr;29(11):1676-85
pubmed: 18192005
Expert Opin Drug Deliv. 2008 Nov;5(11):1185-98
pubmed: 18976130
Nanomedicine (Lond). 2009 Feb;4(2):219-41
pubmed: 19193187
Expert Opin Drug Deliv. 2009 May;6(5):499-508
pubmed: 19413457
Toxicology. 2009 Apr 28;258(2-3):139-47
pubmed: 19428933
J Biomed Mater Res A. 2010 Jun 1;93(3):1004-15
pubmed: 19743511
Int J Pharm. 2011 Jan 17;403(1-2):254-61
pubmed: 20971175
J Control Release. 2012 Jun 10;160(2):394-400
pubmed: 22210161
Int J Pharm. 2012 Apr 15;426(1-2):271-279
pubmed: 22322210
Trends Biotechnol. 2014 Jan;32(1):32-45
pubmed: 24210498
Trends Mol Med. 2014 May;20(5):271-81
pubmed: 24594264
Biomed Res Int. 2014;2014:129458
pubmed: 25126543
J Thromb Thrombolysis. 2017 Feb;43(2):184-193
pubmed: 27778144
Artif Cells Nanomed Biotechnol. 2017 Dec;45(8):1478-1489
pubmed: 28278584
Colloids Surf B Biointerfaces. 2017 Oct 1;158:507-517
pubmed: 28738290
Iran J Biotechnol. 2016 Jun;14(2):33-40
pubmed: 28959324
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
J Biomed Mater Res. 1993 May;27(5):683-95
pubmed: 8390998
Biochim Biophys Acta. 1997 Oct 23;1329(2):345-56
pubmed: 9371426